Literature DB >> 24986674

The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Ravi Chopra1, Vikram G Shakkottai.   

Abstract

Polyglutamine diseases are a class of neurodegenerative diseases that share an expansion of a glutamine-encoding CAG tract in the respective disease genes as a central hallmark. In all of these diseases there is progressive degeneration in a select subset of neurons, and the mechanisms behind this degeneration remain unclear. Emerging evidence from animal models of disease has identified abnormalities in synaptic signaling and intrinsic excitability in affected neurons, which coincide with the onset of symptoms and precede apparent neuropathology. The appearance of these early changes suggests that altered neuronal activity might be an important component of network dysfunction and that these alterations in network physiology could contribute to symptoms of disease. Here we review abnormalities in neuronal function that have been identified in both animal models and patients, and highlight ways in which these changes in neuronal activity may contribute to disease symptoms. We then review the literature supporting an emerging role for abnormalities in neuronal activity as a driver of neurodegeneration. Finally, we identify common themes that emerge from studies of neuronal dysfunction in polyglutamine disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24986674      PMCID: PMC4391381          DOI: 10.1007/s13311-014-0289-7

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  108 in total

1.  An expanded CAG repeat sequence in spinocerebellar ataxia type 7.

Authors:  K Lindblad; M L Savontaus; G Stevanin; M Holmberg; K Digre; C Zander; H Ehrsson; G David; A Benomar; E Nikoskelainen; Y Trottier; G Holmgren; L J Ptacek; A Anttinen; A Brice; M Schalling
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

2.  Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice.

Authors:  Adebimpe W Kasumu; Xia Liang; Polina Egorova; Daria Vorontsova; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2012-09-12       Impact factor: 6.167

3.  Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2).

Authors:  K Gierga; K Bürk; M Bauer; G Orozco Diaz; G Auburger; C Schultz; M Vuksic; L Schöls; R A I de Vos; H Braak; T Deller; U Rüb
Journal:  Acta Neuropathol       Date:  2005-05-19       Impact factor: 17.088

Review 4.  Spinocerebellar ataxia type 1.

Authors:  Stefano Di Donato; Caterina Mariotti; Franco Taroni
Journal:  Handb Clin Neurol       Date:  2012

5.  TrkB/BDNF-dependent striatal plasticity and behavior in a genetic model of epilepsy: modulation by valproic acid.

Authors:  Veronica Ghiglieri; Carmelo Sgobio; Stefano Patassini; Vincenza Bagetta; Anna Fejtova; Carmela Giampà; Silvia Marinucci; Alexandra Heyden; Eckart D Gundelfinger; Francesca R Fusco; Paolo Calabresi; Barbara Picconi
Journal:  Neuropsychopharmacology       Date:  2010-03-03       Impact factor: 7.853

6.  Abnormalities in the climbing fiber-Purkinje cell circuitry contribute to neuronal dysfunction in ATXN1[82Q] mice.

Authors:  Justin A Barnes; Blake A Ebner; Lisa A Duvick; Wangcai Gao; Gang Chen; Harry T Orr; Timothy J Ebner
Journal:  J Neurosci       Date:  2011-09-07       Impact factor: 6.167

7.  Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Angela Venegas; Yeranui Gomez; Michael S Levine
Journal:  J Neurophysiol       Date:  2005-12-28       Impact factor: 2.714

Review 8.  Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance.

Authors:  U Rüb; D Del Turco; K Del Tredici; R A I de Vos; E R Brunt; G Reifenberger; C Seifried; C Schultz; G Auburger; H Braak
Journal:  Brain       Date:  2003-07-07       Impact factor: 13.501

9.  SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

Authors:  E N Burright; H B Clark; A Servadio; T Matilla; R M Feddersen; W S Yunis; L A Duvick; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1995-09-22       Impact factor: 41.582

10.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease.

Authors:  Xiaofeng Gu; Véronique M André; Carlos Cepeda; Shi-Hua Li; Xiao-Jiang Li; Michael S Levine; X William Yang
Journal:  Mol Neurodegener       Date:  2007-04-30       Impact factor: 14.195

View more
  14 in total

1.  Neurogenetic disease: genes, mechanisms, and future promise.

Authors:  William T Dauer
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

2.  Assembly of Huntingtin headpiece into α-helical bundles.

Authors:  Beytullah Ozgur; Mehmet Sayar
Journal:  Biointerphases       Date:  2017-05-24       Impact factor: 2.456

3.  Paradigm for disease deconvolution in rare neurodegenerative disorders in Indian population: insights from studies in cerebellar ataxias.

Authors:  Renu Kumari; Deepak Kumar; Samir K Brahmachari; Achal K Srivastava; Mohammed Faruq; Mitali Mukerji
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  Chronic Pharmacological Increase of Neuronal Activity Improves Sensory-Motor Dysfunction in Spinal Muscular Atrophy Mice.

Authors:  Christian M Simon; Beatriz Blanco-Redondo; Jannik M Buettner; John G Pagiazitis; Emily V Fletcher; Josiane K Sime Longang; George Z Mentis
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

5.  ClC-2-like Chloride Current Alterations in a Cell Model of Spinal and Bulbar Muscular Atrophy, a Polyglutamine Disease.

Authors:  Vladimir A Martínez-Rojas; Aura M Jiménez-Garduño; Daniela Michelatti; Laura Tosatto; Marta Marchioretto; Daniele Arosio; Manuela Basso; Maria Pennuto; Carlo Musio
Journal:  J Mol Neurosci       Date:  2020-08-28       Impact factor: 3.444

Review 6.  Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease.

Authors:  David D Bushart; Geoffrey G Murphy; Vikram G Shakkottai
Journal:  Ann Transl Med       Date:  2016-01

7.  Potassium channel dysfunction underlies Purkinje neuron spiking abnormalities in spinocerebellar ataxia type 2.

Authors:  James M Dell'Orco; Stefan M Pulst; Vikram G Shakkottai
Journal:  Hum Mol Genet       Date:  2017-10-15       Impact factor: 6.150

8.  Clenbuterol-sensitive delayed outward potassium currents in a cell model of spinal and bulbar muscular atrophy.

Authors:  Vladimir A Martínez-Rojas; Daniele Arosio; Maria Pennuto; Carlo Musio
Journal:  Pflugers Arch       Date:  2021-05-22       Impact factor: 3.657

Review 9.  Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia.

Authors:  Lauren M Watson; Maggie M K Wong; Esther B E Becker
Journal:  Open Biol       Date:  2015-07       Impact factor: 6.411

Review 10.  Motor Dysfunctions and Neuropathology in Mouse Models of Spinocerebellar Ataxia Type 2: A Comprehensive Review.

Authors:  João M Da Conceição Alves-Cruzeiro; Liliana Mendonça; Luís Pereira de Almeida; Clévio Nóbrega
Journal:  Front Neurosci       Date:  2016-12-15       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.